{
    "2019-10-30": [
        [
            {
                "time": "",
                "original_text": "当亚文化走向主流 B站商业化提速",
                "features": {
                    "keywords": [
                        "亚文化",
                        "B站",
                        "商业化"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "娱乐",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "传统药企联姻创新药企再上演：云南白药3.5亿元基石投资中国抗体",
                "features": {
                    "keywords": [
                        "云南白药",
                        "中国抗体",
                        "投资"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【国盛证券张金洋团队】恒瑞医药：两大品种申报上市，在研管线超预期推进",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "新药上市",
                        "研发"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中国抗体获云南白药基石投资3.5亿元，将香港本土Biotech第一股",
                "features": {
                    "keywords": [
                        "中国抗体",
                        "云南白药",
                        "投资",
                        "Biotech"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国产牙膏两面针连亏13年，与外资牙膏打价格战，躲进酒店做医药 亏损",
                "features": {
                    "keywords": [
                        "两面针",
                        "亏损",
                        "价格战",
                        "医药"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "日化",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "每次大盘回调，这些板块最抗跌？今日关注两大投资机会！",
                "features": {
                    "keywords": [
                        "大盘回调",
                        "抗跌板块",
                        "投资机会"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "市场分析"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "云南白药2019年三季报点评:三季报显著超预期,药品与健康品重拾两位数增长",
                "features": {
                    "keywords": [
                        "云南白药",
                        "三季报",
                        "超预期",
                        "增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}